CA2773998A1 — Substituted carbonyl compound
Assigned to Ube Corp · Expires 2011-03-17 · 15y expired
What this patent protects
Novel substituted carbonyl compounds represented by general formula (I) or salts thereof, which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity and which are useful in the treatment of respiratory diseases. In general formula (I), R1 is -OR5, -…
USPTO Abstract
Novel substituted carbonyl compounds represented by general formula (I) or salts thereof, which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity and which are useful in the treatment of respiratory diseases. In general formula (I), R1 is -OR5, -O(CH2CH2O)mR6 or -NR7R8 (wherein R5 is C7-22 alkyl or the like; R6 is H or benzyl; m is 1 to 4; and R7 and R8 are each H, C1-12 alkyl, or the like); R2 and R3 are each H or C1-6 alkyl; Y is a (substituted) bicyclic heteroaromatic ring, -Q1-Q2, or the like (wherein Q1 is arylene or the like; and Q2 is a (substituted) 5- or 6-memebred heterocycle, or the like); and Z is (substituted) aryl or a (substituted) 5- or 6-memeberd heteroaromatic ring.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.